Home About Us Resource News & Events Sites
Building Blocks

News & Events Menus

PharmaBlock Enters Strategic Partnership with Ascentage Pharma

This article was orginally published in PR Newswire website.


PharmaBlock Sciences (Nanjing), Inc. (300725.SZ), a leading innovative chemistry product and service provider throughout the pharmaceutical R&D process, announced the signing of a strategic partnership agreement with Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases. The partnership aims to strengthen the strategic cooperation between the two companies in drug development and manufacturing. 

image.png

image.png

Dr. Ming Guo and Dr. Haijun Dong signed the strategic partnership agreement


As a long-term CDMO partner of Ascentage Pharma, PharmaBlock has witnessed many of its development projects advancing quickly from discovery to preclinical and clinical manufacturing. Under the terms of the agreement, PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and future projects. PharmaBlock will fully support Ascentage Pharma to accelerate its novel drug development pipeline with the most sufficient R&D input and manufacturing capacity, along with its innovative technological solutions.

 

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to block apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US Food and Drug Administration (FDA), and an NDA for the drug has been submitted in China. To date, Ascentage Pharma has obtained a total of eight ODDs from the FDA for four of the company’s investigational drug candidates.

image.png

Group photo of the leadership teams of Ascentage Pharma and PharmaBlock


Dr. Ming GUO, Co-founder and CEO of Ascentage Pharma, said: "PharmaBlock is a reliable and trusted business partner of Ascentage. We appreciate the dedication and professionalism of the PharmaBlock team. I believe that the strategic partnership between the two companies will definitely help us accelerate the new drug development pipeline towards the commercial stage."

 

Led by an experienced management and core technical team, PharmaBlock has been providing top-standard development and manufacturing solutions of RSMs, intermediates, and APIs for both the drug development and commercial stages. Taking full advantage of its building block capabilities, along with its know-how in chemistry, process development, analytical development, manufacturing and engineering technologies etc., the team has distinguished itself by showing great skill in tackling challenging chemistry, securing reliable supply, controlling costs, and maintaining  full compliance of quality and EHS, etc. To further realize safe, efficient and green process development and manufacturing, PharmaBlock has developed an advanced chemistry and engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, crystallization, solid state chemistry, etc. Their technology platform has enabled more innovative solutions, with shortened lead time and reduced overall costs for development and manufacturing projects.

 

 “With a rich pipeline of assets with first- and best-in-class potentials, Ascentage Pharma is a leading innovative biotechnology company in China with a global footprint. We are so proud to support companies like Ascentage to discover and develop next generation of medicines much needed by the patients," commented Dr. Haijun Dong, CEO of PharmaBlock.